ISRCTN12840543已完成1 期
A five-part, Phase I, open-label, drug-drug interaction study examining the effect of gemfibrozil, fluconazole and carbamazepine on the safety, tolerability and pharmacokinetics of REN001, and the effect of REN001 on the safety, tolerability and pharmacokinetics of fexofenadine and rosuvastatin in healthy subjects
Reneo Pharma Ltd (United Kingdom)0 个研究点目标入组 83 人开始时间: 2022年11月25日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 83
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Healthy male and female subjects, between 18 and 60 years of age, inclusive.
- •2. Female subject with a negative pregnancy test at Screening.
- •3. Subjects must agree to adhere to the contraception requirements defined in the study protocol.
- •4. Subject with a body mass index (BMI) of 18-32 kg/m2 (BMI = body weight (kg) / [height (m)]2)
- •5. No clinically significant history of previous allergy/sensitivity to REN001, gemfibrozil, fluconazole, fexofenadine, rosuvastatin, carbamazepine or any of the excipients contained within the IMP/NIMPs.
- •6. No clinically significant abnormal test results for serum biochemistry, haematology, coagulation and/or urine analyses within 35 days before the first dose administration of the IMP/NIMP.
- •7. Subject with a negative urinary drugs of abuse (DOA) screen (including alcohol) test results, determined within 35 days before the first dose administration of the IMP/NIMP (N.B.: A positive test result may be repeated at the Investigator’s discretion).
- •8. Subject with negative human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg)) and hepatitis C virus antibody (HCV Ab) test results at Screening.
- •9. No clinically significant abnormalities in 12-lead electrocardiogram (ECG) determined within 35 days before first dose of IMP/NIMP including a PR interval >220 ms, QT interval heart rate corrected using Fridericia’s formula QTcF >450 ms.
- •10. No clinically significant abnormalities in vital signs (e.g., blood pressure, pulse, respiratory rate and oral temperature) determined within 35 days before first dose of IMP/NIMP.
- •11. Subject must be available to complete the study (including all follow-up visits).
- •12. Subject must satisfy an Investigator about his/her fitness to participate in the study.
- •13. Subject must provide written informed consent to participate in the study.
排除标准
- •1. A clinically significant history of gastrointestinal disorder likely to influence IMP/NIMP administration and absorption.
- •2. Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 35 days or 5 half-lives (whichever is longer) prior to the first dose of IMP/NIMP with the exception of paracetamol (which may be taken as an analgesic to a maximum of 2 g in 24 h) and ibuprofen (which may be taken as an analgesic to a maximum of 1.2 g in 24 h [400 mg 3 times a day]).
- •3. Subjects who have previously received REN001.
- •4. Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular or metabolic dysfunction.
- •5. Suitable veins for venepuncture and cannulation.
- •6. Presence or history of clinically significant allergy requiring treatment, as judged by the Investigator. Hay Fever is allowed unless active.
- •7. A clinically significant history of drug or alcohol abuse (defined as the consumption of more than 14 units [for male and female subjects] of alcohol a week) within the past two years.
- •8. Medical history that would preclude the administration of the NIMPs.
- •9. Inability to communicate well with the Investigators (i.e., language problem, poor mental development or impaired cerebral function).
- •10. Participation in a New Chemical Entity (NCE) clinical study within the previous 3 months or five half-lives, whichever is longer, or a marketed drug clinical study within 30 days or five half-lives, whichever is longer, before the first dose of IMP/NIMP. (The washout period between studies is defined as the period of time elapsed between the last dose of the previous study and the first dose of the next study).
- •11. Donation or loss of 450 mL or more blood within the 3 months before the first dose of IMP/NIMP or no plans to donate blood in the 3 months following completion of the study.
- •12. Vegans, vegetarians or other dietary restrictions (e.g., restrictions for medical, religious or cultural reasons, etc) that would prevent the subject from consuming a standardised meal or gelatine capsule.
- •13. Willing and able to swallow gelatin capsules.
- •14. Users of nicotine products i.e., current smokers or ex-smokers who have smoked within the 6 months prior to Screening or users of cigarette replacements (i.e., e-cigarettes, nicotine patches or gums).
- •15. Female subjects who are pregnant, breastfeeding or lactating.
- •16. Subjects who have received a COVID-19 vaccine injection within 35 days prior to the first dose of IMP/NIMP.
研究者
相似试验
尚未招募
不适用
A phase I, multi-center, open-label, drug-drug interaction study to assess the effect of the CYP1A2 inhibitor, fluvoxamine, on TKI258 (dovitinib) pharmacokinetics in patients with advanced solid tumors.advanced cancersolid tumors10027655NL-OMON39285ovartis12
进行中（未招募）
1 期
A study to evaluate the safety, processing by the body and response of the body to tenecteplase in adults with acute ischemic strokeISRCTN13376195Roche (United States)20
已完成
不适用
A phase 1, open-label, fixed-sequence, drug-drug interaction study of APX001 to evaluate the effects of CYP3A4 inhibition and pan-CYP induction in two parallel groups of healthy male and female subjectsFungal infectionsNL-OMON47992Amplyx Pharmaceuticals, Inc.36
已完成
不适用
A phase 1, open-label, fixed-sequence, drug-drug interaction study between multiple oral doses of Inarigivir Soproxil and a single oral dose of midazolam in healthy subjectsHepatitis BNL-OMON46790Spring Bank Pharmaceuticals, Inc.16
已完成
不适用
A Phase 1, Open-Label, Multicenter, Drug-Drug Interaction Study of TAK-788 and Midazolam, a Sensitive CYP3A Substrate, in Patients With Advanced Non*Small Cell Lung Cancerlung tumorLung cancerNL-OMON49519Millenium Pharmaceuticals6